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ABSTRACT 
Isoxazole is a five membered heterocyclic compound containing oxygen and nitrogen 
atoms in the 1,2 positions. Isoxazole rings are found in natural products, such as ibotenic 
acid and muscimol. The isoxazole structure is incorporated in a variety of pharmaceutical 
agents. Substitution on different positions on the nucleus of the isoxazole results in various 
pharmacological effects. Specifically, isoxazole compounds are used in various types of 
pharmaceutical compounds to treat bacterial infections and pain relief. Oxidative 
cycloaddition of aldoximes with unsaturated substrates provides an efficient approach to 
the formation of heterocyclic compounds. More specifically, various isoxazoles can be 
easily prepared by the oxidative cycloaddition of aldoximes with unsaturated substrates in 
the presence of hypervalent iodine(III) reagents. Oxidation of aldoximes by hypervalent 
iodine(III) compounds produces nitrile oxides which further react with respective 
unsaturated substrates through a 1,3-dipolar cycloaddition reaction resulting in various 
isoxazole products. This technique is an efficient process that utilizes green chemistry. 
Here, we report an efficient synthetic approach for preparation of various regioselective 
3,4-substituted isoxazoles and 3,4,5-substituted isoxazoles using 
[hydroxy(tosyloxy)iodo]benzene, commonly known as Koser’s reagent. To our knowledge, 
this is the first time the 3,4-substituted isoxazole has been prepared. The oxidative 
cycloaddition proceeds at room temperature resulting in moderate to high yields. Structures 
of several isoxazole derivatives were established by X-ray crystallography. These 
isoxazole derivatives are stable compounds that have the potential to be useful for 
biologically active molecules and pharmaceutical reagents.
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CHAPTER 1: Hypervalent Iodine 
 Iodine is known as the heaviest atom in the Periodic Table classified as a non-
radioactive element and nonmetal.1 One of the most important aspects of iodine is its 
ability to become hypervalent. Iodine is commonly seen in organic compounds as 
trivalent and pentavalent hypervalent iodine compounds.1 Hypervalent iodine is used for 
many organic synthesis reactions such as halogenation reactions, oxidations, 
rearrangements, bond-forming reactions, and catalytic reactions.1-2 Specifically, 
hypervalent iodine reagents are used for various oxidative transformations as they have 
characteristics that are similar to metals, while being non-toxic, environmentally friendly, 
commercially available, and relatively inexpensive.1-3 Furthermore, they offer heteroatom 
ligands, mild reaction conditions, and rapid synthesis.3-4 Hypervalent iodine(III) is known 
for its strong electrophilic characteristics and very high leaving group ability.1,3 
Hypervalent iodine reagents are commonly known for oxidative addition, ligand 
exchange, reductive elimination, ligand coupling, and catalyst.1 More specifically, many 
reactions with hypervalent iodine reagents involve the two-step oxidative process of 
ligand exchange and reductive elimination (Scheme 1). The process starts with an 
external nucleophilic attack on hypervalent iodine(III) atom resulting in a ligand 
displacement followed by the reductive elimination of iodobenzene.1,3. This process is 
energetically favorable as it is associated with an increase in entropy.3 Hypervalent 
iodine(III) is at the forefront of “green chemistry” for oxidative transformations. 
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Scheme 1. Ligand exchange and reductive elimination using hypervalent iodine(III) 
 
 
CHAPTER 2: Isoxazole Compounds 
 Isoxazole is a five membered heterocyclic compound containing oxygen and 
nitrogen atoms in the 1,2-positions. Isoxazole rings are found in natural products, such as 
ibotenic acid and muscimol found in mushrooms (Figure 1).5-6  
 
Figure 1. Natural products containing the isoxazole ring 
 Isoxazole compounds are incorporated in a variety of biologically active 
molecules and pharmaceutical reagents.7 Specifically, the isoxazole ring is found in a 
variety of b-lactamase-resistant antibiotics, such as oxacillin, cloxacillin, and 
dicloxacillin, as well as in COX-2 inhibitors, such as valdecoxib (Figure 2).8 Substitution 
to different positions of the isoxazole ring results in varied pharmaceutical effects. For 
example, these pharmaceutical reagents can treat bacterial infections as well as pain 
relief.8  
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Figure 2. Isoxazole structure incorporated in pharmaceutical agents 
 
 
CHAPTER 3: Reactions Involving Nitrile Oxide 
 The chemistry of nitrile oxides has been studies in great detail over many years.9 
Particularly, aldoximes are good precursors for the generation of nitrile oxide species in 
situ with hypervalent iodine(III). Oxidative cyclization of aldoximes using hypervalent 
iodine(III) reagents provides an efficient synthetic approach to many five-membered 
heterocyclic systems.9 Hypervalent iodine(III) mediated oxidation of aldoximes generates 
nitrile oxides which can further react with respective substrates via intermolecular or 
intramolecular 1,3-dipolar cycloaddition reactions resulting in various heterocyclic 
compounds.10-11 Intermolecular nitrile oxide cycloadditions have been known for a very 
long time.10-12 Specifically, nitrile oxide can react with alkenes, alkynes, nitriles, and 
aldehydes through the intermolecular 1,3-dipolar cycloaddition to give the respective 
heterocyclic products such as isoxazolines, isoxazoles, oxadiazoles, and dioxazoles.13 
Currently, the generation of isoxazoles and isoxazolines from nitrile oxides for various 
natural products and analogues has been a major focus.14  
 
 
N
S
H H
O
OHH
N
H
O
N
O
Me
Cl
cloxacillin
β-lactamase-resistant antibiotics
N
S
O OH
HHN
O
O
O
N
Cl
Cl
dicloxacillin
H
S
N
O
N
H
O
Me
O
N
HO O
oxacillin
Me
O
N
Me
S NH2
O
O
Bextra
(valdecoxib)
COX-2 inhibitor
Me
Me
Me
Me
Me
Me O
 4 
3.1. Common methods to obtain nitrile oxide 
3.1.1. From aldoxime 
Nitrile oxide was first discovered in 1894 by Werner by the dehydrogenation of 
aldoxime. The nitrile oxide species was prepared by chlorination of benzaldoxime 
followed by base-mediated dehydrochlorination of the resulting benzohydroximoyl 
chloride (Scheme 2).14 This two-phase method is still widely used today.  
 
Scheme 2. Generation of nitrile oxide from aldoxime through chlorination 
 
3.1.2. From aliphatic nitro compounds 
Nitrile oxide can also be generated from nitro compounds utilizing Mukaiyama’s 
procedure. From the procedure, the generation of nitrile oxide is produced by the 
dehydration of primary nitroalkanes with an aryl isocyanate, usually in the presence of 
Et3N as a base (Scheme 3).9  
 
Scheme 3. Generation of nitrile oxide from nitro species 
 
3.1.3. From hypervalent iodine(III) 
Nitrile oxide can also be generated using hypervalent iodine(III) by direct oxidation 
of aldoxime into nitrile oxide species (Scheme 4). Various hypervalent iodine(III) 
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compounds, such as iodobenzene dichloride, iodosylbenzene, (diacetoxyiodo)benzene 
have been used as oxidants.9 
 
Scheme 4. Generation of nitrile oxide from aldoxime using hypervalent iodine(III). 
 
3.2. Nitrile oxide dimerization reaction 
The nitrile oxide species is an unstable and highly reactive compound. While nitrile 
oxides are valuable for 1,3-dipolar cycloaddition reactions, their ability to undergo 
spontaneous dimerization can be used to prepare furoxans.14 Nitrile oxides, especially for 
lower aliphatic and acyl nitrile oxides, can easily dimerize to form 1,2,5-oxadiazole-2-
oxides (Scheme 5).10  
 
Scheme 5. Generation of furoxan species from nitrile oxide dimerization 
 
3.3. Reactions with aldoximes and hypervalent iodine(III) 
3.3.1. Oxidative cycloaddition of aldoxime and alkene 
The generation of nitrile oxide in the presence of alkenes results in the intermolecular 
1,3-dipolar cycloaddition leading to isoxazolines. In 2004, Das et al. reported the reaction 
of substituted benzaldoximes with (diacetoxyiodo)benzene and alkenes to give the 
corresponding isoxazolines in good yields (Scheme 6).15 The presence of an electron-
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donating or an electron-withdrawing group on the aromatic ring of the aldoximes did not 
affect the reaction.15 
 
Scheme 6. Oxidative cycloaddition of aldoxime and alkene 
 
3.3.2. Oxidative cycloaddition of aldoxime and alkyne 
The generation of nitrile oxide in the presence of alkynes results in the intermolecular 
1,3-dipolar cycloaddition leading to isoxazoles. In 2011, Jawalekar et al. reported the 
reaction of aromatic or aliphatic aldoximes with various alkynes using 
[bis(trifluoroacetoxy)iodo]benzene affording the corresponding isoxazole products in 
good yields (Scheme 7).16 The hypervalent iodine(III) induced heterocyclization has been 
used for the efficient synthesis of nucleoside-substituted isoxazoles from aldoximes and 
nucleosides.16  
 
Scheme 7. Oxidative cycloaddition of aldoxime and alkyne 
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3.3.3. Oxidative cycloaddition of aldoxime and nitrile 
The generation of nitrile oxide in the presence of nitriles results in the intermolecular 
1,3-dipolar cycloaddition leading to oxadiazoles. In 2016, Yoshimura et al. reported the 
treatment of aliphatic and aromatic aldoximes with IBA-OTf in acetonitrile solution to 
form the corresponding oxadiazoles in moderate to good yields (Scheme 8).17  The 
reaction also proceeds smoothly in solutions of other nitriles under similar conditions 
affording 1,2,4-oxadiazoles in moderate to good yields.17 
 
Scheme 8. Oxidative cycloaddition of aldoxime and nitrile 
 
3.3.4. Oxidative cycloaddition of benzaldoxime and benzaldehyde 
The generation of nitrile oxide in the presence of aldehydes results in the 
intermolecular 1,3-dipolar cycloaddition leading to dioxazoles. In 2002, Tanaka et al. 
reported the oxidative cycloaddition reaction of aldoxime with aldehyde using 
hypervalent iodine(III).18 For example, the reaction of benzaldoxime with benzaldehyde 
using iodosylbenzene (PhIO) results in the product 3,5-diphenyl-1,2,4-dioxazole in low 
yield (Scheme 9). 
 
Scheme 9. Oxidative cycloaddition of benzaldoxime and benzaldehyde 
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3.3.5. Oxidative cycloaddition of benzaldoxime and maleimide 
Nitrile oxides can further react with symmetrical heterocyclic alkenes to obtain 
pyrrolo-isoxazoles. In 2016, Yoshimura, Nguyen, et al. developed an efficient 
cycloaddition of heterocyclic alkenes with nitrile oxide species in situ from aldoximes 
using IBA-OTf (Scheme 10).19 The corresponding heterocycles were obtained in 
moderate to high yields. This method was also developed in catalytic conditions.19 
 
Scheme 10. Oxidative cycloaddition of benzaldoxime and maleimide 
 
3.3.6. Oxidative cycloaddition of aldoxime with sultone and phospholene  
Nitrile oxides can further react with asymmetrical heterocyclic alkenes to obtain 
isoxazoline-ring-fused heterobicyclic and heterobicyclic phospholene oxide products. In 
2017, Yoshimura, Nguyen, et al. developed an efficient regioselective cycloaddition of 
heterocyclic alkenes with nitrile oxide species in situ from aldoximes using 
[hydroxy(tosyloxy)iodo]benzene (Scheme 11).20 First, the oxidative cycloaddition of 
various aldoximes with 1-propene-1,3-sultone resulted in the respective isooxazoline-
ring-fused heterobicyclic products in moderate to good yields.20 Next, the reaction of 
aldoxime with 3-methyl-1-phenyl-2-phospholene-1-oxide under similar conditions 
resulted in the corresponding heterobicyclic phospholene oxides in moderate yields.20 
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Scheme 11. Oxidative cycloaddition of aldoxime with sultone and phospholene 
  
 The generation of the 3,4,5-substituted isoxazoles from oximes and asymmetrical 
heterocyclic alkenes reported by our group in 2017 inspired us to synthesize the first 3,4-
substituted isoxazole regioselectively by hypervalent iodine(III) using aliphatic 
unsaturated substrates. From the idea that the high electron withdrawing nature of the 
sultone and phospholene created a dipole within the unsaturated substrate allowing for 
regioselectivity in the electrostatic attraction with nitrile oxide, we hypothesized that we 
could modify an aliphatic unsaturated substrate to react with nitrile oxide. This idea 
inspired us to create the 3,4-substituted isoxazole by reacting the hypervalent iodine(III) 
mediated nitrile oxide with an aliphatic unsaturated substrate that possessed a dipole.  
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Chapter 4: Results and Discussion 
4.1. The aim of research 
 The aim of this research is to prepare 3,4-substituted isoxazoles and 3,4,5-
substituted isoxazoles 4 regioselectively by hypervalent iodine(III)-mediated 1,3-dipolar 
cycloaddition of aldoximes 1 with enaminones 2. The hypervalent iodine(III) species 
[hydroxy(tosyloxy)iodo]benzene 3a was used in the reaction to oxidize aldoxime into 
nitrile oxide. To our knowledge, this is the first time that hypervalent iodine(III) could be 
utilized with aldoximes to create the regioselective 3,4-substitued isoxazoles.  
 
Scheme 12. Koser’s reagent mediate oxidative cycloaddition of aldoxime with 
enaminone 
 
Table 1. Optimization of oxidative cycloaddition of (E)-benzaldehyde oxime 1a with 
trans-4-dimethylamino-3-buten-2-one 2a using iodine(III) reagents 3a 
 
R1 N
OH
R2
O
NMe2 CH2Cl2, rt, 1.5-24 hr
ON
R1
O R2
+
R3 R3PhI(OH)OTs 3a
1 2
4
Me
O
NMe2
ArI(III) 3 (1.2-2 equiv.)
solvent, time, rt
N O
Me O
N OH
1a
(1 equiv.)
2a
(2-3 equiv.) 4a
I OAcAcOO
OH
IHO
OTf
I O I OCOCF3F3COCOI OHO
O
3b 3d3c 3e 3f
+
I OHTsO
3a
 11 
Entry Time (h) Solvent Enaminone 2a 
(equiv) 
ArI(III) 4a (%) 
a,b 
1 3h CH2Cl2 2 DIB 3d (2) 34 
2 3h CH2Cl2 2 IBA 3b (2) none  
3 3h CH2Cl2 2 IBA-OTf  3c (2) trace 
4 3h CH2Cl2 2 HTIB 3a (2) 76 
5 6h CH2Cl2 2 HTIB 3a (2) 55 
6 24h CH2Cl2 2 HTIB 3a (2) 64 
7 3h CH2Cl2 3 HTIB 3a (2) 94 (92) 
8 3h CH2Cl2 3 DIB 3d (2) 49 
9 3h CH2Cl2 3 PhIO 3e (2) 16 
10 3h CH2Cl2 3 PIFA 3f (2) 8 
11 3h CHCl3 3 HTIB 3a (2) 90 
12 3h ClCH2CH2Cl 3 HTIB 3a (2) 76 
13 3h Heptane 3 HTIB 3a (2) 11 
14 3h MeCN 3 HTIB 3a (2) 80 
15 3h AcOEt 3 HTIB 3a (2) 32 
16 3h MeOH 3 HTIB 3a (2) 91 
17c 3h CH2Cl2 3 HTIB 3a (2) (85) 
18 3h CH2Cl2 3 HTIB 3a (1.2) 82 (67) 
 
aReaction conditions: (E)-Benzaldehyde oxime 1a (0.250 mmol; 1 equiv) and trans-2-
dimethylamino-3-buten-2-one 2a (0.500-0.750 mmol; 2-3 equiv) with iodine(III) reagent 
3 (0.500-0.600 mmol; 1.2-2 equiv) in various solvents were stirred for 3-24 h at room 
temperature. bYields of product 4a determined from 1H spectra of reaction mixtures are 
shown (numbers in parentheses show yields of 4a after column chromatography). cLarge 
scale experiment: (E)-Benzaldehyde oxime 1a (1.00 mmol; 1 equiv), trans-4-
 12 
dimethylamino-3-buten-2-one 2a (3 mmol; 3 equiv), and Koser’s reagent 3a (2 mmol; 2 
equiv) in DCM were stirred for 3 h at room temperature. 
 
4.2. Optimization study using trans-4-dimethylamino-3-buten-2-one 
 First, we have tested the oxidative cycloaddition of (E)-benzaldehyde oxime 1a (1 
equiv) with trans-4-dimethylamino-3-buten-2-one 2a (2-3 equiv) in several solvents 
using Koser’s reagent 3a (2 equiv). We have found that dichloromethane is the best 
solvent for the formation of the desired product 4a using reagent 3a (Table 1, entries 7, 
11−16). Screening of the other hypervalent iodine(III) reagents 3b−3f has demonstrated 
that Koser’s reagent 3a is the most efficient oxidant in this cycloaddition (entries 1-4, 7-
10). Decreasing the amount of Koser’s reagent 3a verified that 2 equivalence gave the 
best yield for this reaction (entries 7, 18). For the reactions of Koser’s reagent 3a in 
dichloromethane, 3 hours gave the best yields for the reaction and increasing the reaction 
time resulted in lower yields of product 4a (entries 4-6). Increasing the amount of trans-
4-dimethylamino-3-buten-2-one 2a resulted in a higher yield of product 4a (entries 4, 7). 
This oxidative cycloaddition is also applicable on a larger scale using millimolar 
quantities of reagents. Specifically, the reaction of (E)-benzaldehyde oxime 1a (1 mmol) 
with trans-4-dimethylamino-3-buten-2-one 2a (3 mmol) using Koser’s reagent 3a (2 
mmol) under optimized conditions afforded product 4a in 85% yield (entry 17). 
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Table 2. Oxidative cycloaddition of aldoximes 1 with trans-4-dimethylamino-3-buten-2-
one 2a using Koser’s reagent 3aa,b  
 
aReaction conditions: Aldoxime 1 (0.250 mmol; 1 equiv) and trans-2-dimethylamino-3-
buten-2-one 2a (0.750 mmol; 3 equiv) with Koser’s reagent 3a (0.500 mmol; 2 equiv) in 
Ph N OH Me
O
NMe2
PhI(OH)OTs 3a (2 equiv.)
CH2Cl2, rt, 3-24 h
1a
(1 equiv.)
2a
(3 equiv.)
4a
92% (85%)d
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O Me
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DCM were stirred for 3-24 h at room temperature. bYields of products after column 
chromatography. cNMR yields of products. dLarge scale experiment: (E)-benzaldehyde  
oxime 1a (1.00 mmol; 1 equiv), trans-4-dimethylamino-3-buten-2-one 2a (3 mmol; 3 
equiv), and Koser’s reagent 3a (2 mmol; 2 equiv) in DCM were stirred for 3 h at room 
temperature. eReaction conditions: 1,4-benezedicarboxaldehyde 1am (0.125 mmol; 1 
equiv) and trans-2-dimethylamino-3-buten-2-one 2a (0.750 mmol; 6 equiv) with Koser’s 
reagent 3a (0.500 mmol; 4 equiv) in DCM were stirred for 24 h at room temperature. 
 
4.3. Substrate scope study using trans-4-dimethylamino-3-buten-2-one 
Using the optimized conditions with Koser’s reagent 3a, we have investigated the 
reaction of various substituted aldoximes 1 with trans-4-dimethylamino-3-buten-2-one 2a 
leading to the respective isoxazole products 4 (Table 2). The structures of products 4a, 4t, 
and 4u were established by X-ray crystallography (see Figures S1, S2, and S3 in the 
experimental section). In general, substitution of (E)-benzaldehyde oxime 1a with either 
electron-donating or electron-withdrawing groups, under optimized reaction conditions, 
afforded target products 4a−x in moderate to good yields with excellent regioselectivity.  
 The reactions of sterically hindered aldoximes, such as 2,6-dimethyl-
benzaldoxime 1p or 2,6-dicholorobenzaldoxime 1e, gave the corresponding products 4p 
and 4e in moderate to good yields. Interestingly, the presence of bulky chlorine groups in 
1e and 1c corresponding to products 4e and 4c were still isolated in good yields of 91% 
and 81%, respectively. This result is likely due to the domination of electrostatic effect 
over steric effect.  
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The reactions of electron rich aldoximes, such as 4-(methylthio)benzaldehyde 
oxime 1t, 2-hydroxybenzaldehyde oxime 1y, (E)-furan-2-carbaldehyde oxime 1z, and 
(E)-picolinaldehyde oxime 1aa, resulted in the corresponding products 4t, 4y, 4z, 4aa in 
moderate to low yields. In particular, the yield of product 4t was low (34%), probably 
due to competitive oxidation on sulfur.21 However, we were not able to detect the 
corresponding sulfoxides in the reaction mixture. Product 4y was not isolated as this 
product produced a complex mixture that could not be isolated as a clean product. From 
Raymond et al. 2015, it is known that Boulton-Katritzky rearrangement and Neber 
rearrangement can occur on O-hydroxy isoxazole compounds.22 Therefore, we believe 
this product may have decomposed or rearranged into an unstable derivative. 
Interestingly, when the reaction with (E)-furan-2-carbaldehyde oxime 1z was modified 
with an additional nitro group, (E)-5-nitrofuran-2-carbaldehyde oxime 1m, the 
corresponding products 4z and 4m increased from (13%) to 93%. This can be attributed 
to the high electron withdrawing properties of nitro pulling electron density off furan, 
therefore ceasing oxidative competition between furan and Koser’s reagent and allowing 
the reaction to proceed. If we were able to modify the pyridine reactant 1aa with a nitro, 
we would hypothesize that the yield would increase, but the reaction was not further 
studied.   
 The reactions of aliphatic aldoximes, such as (1E, 2E)-cinnamaldehyde oxime 1v, 
(E)-3-phenylpropanal oxime 1w, and butyraldoxime 1x, gave the corresponding products 
4v, 4w, 4x in moderate to low yields. This lowered yield can be attributed to the 
relatively low stability of the aliphatic nitrile oxides towards oxidation. Specifically, 
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aliphatic nitrile oxides can easily dimerize into the furoxan species6, which was observed 
in the case of butyraldoxime 1x.    
The reaction of 1,4-Benzenedicarboxaldeyde 1am gave the corresponding 
detected product 4am in low yield but was not isolated cleanly. This lowered yield could 
be attributed to the need for an increased amount of oxidative reagent, but this reaction 
was not further studied.  
 
4.4. Reaction mechanism study: Generation of nitrile oxide  
 Control experiments were performed to study the mechanism of the 1,3-dipolar 
cycloaddition of benzaldoximes with enaminones. In the proposed mechanism, the 
generation of nitrile oxide proceeds by a two-step method consisting of ligand exchange 
and reductive elimination (Scheme 13). In order to confirm the ligand exchange step of 
the oxidation mechanism proceeds, a methoxy aldoxime was used in place of the 
aldoxime reagent. The methoxy aldoxime provides a protecting group in place of the 
hydroxy group on (E)-benzaldehyde oxime 1a. After the blank study was ran, the desired 
product was not detected and the methoxy aldoxime was recovered (Scheme 14). This 
confirms that the ligand exchange step is important for the reaction mechanism for the 
generation of nitrile oxide. Next, in order to confirm the reductive elimination step of the 
oxidation mechanism proceeds, a ketoxime was used in place of the aldoxime reagent. 
The ketoxime provides a protecting group in place of the a-hydrogen on (E)-
benzaldehyde oxime 1a. After the blank study was ran, the desired product was not 
detected and ketoxime and the side product acetophenone were recovered (Scheme 14).  
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This confirms that the reductive elimination step is important in the reaction mechanism 
for the generation of nitrile oxide. These blank studies helped confirm that the generation 
of nitrile oxide from aldoxime using hypervalent iodine(III) proceeds first by ligand 
exchange and reductive elimination.           
 
Scheme 13. Proposed reaction mechanism for the generation of nitrile oxide from 
aldoxime using Koser’s reagent 
 
 
Scheme 14. Blank experiments for mechanistic studies for the generation of nitrile oxide 
 
4.5. 1,3-Dipolar cycloaddition mechanism  
Generation of the unstable nitrile oxide species results in the reaction with 
unsaturated compounds by 1,3-dipolar cycloaddition to create heterocyclic rings. Due to 
the resonance structures observed within the unsaturated enaminone substrate, the 
cycloaddition of nitrile oxide with enaminone occurs regioselectivity. By observing the 
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resonance structures between A, B, and C of trans-4-dimethylamino-3-buten-2-one 2a 
(Figure 3), the electron donating amine and electron withdrawing ketone can effectively  
 
delocalize the negative charge by the resonance effect. This resonance creates a dipole 
within the enaminone substrate that allows for a partial postitive and partial negative 
within the double bond of the enaminone structure. This dipole then favors the attractive 
electrostatic interaction with nitrile oxide. Therefore, cycloaddition of nitrile oxides with 
enaminones is more favored if the negatively charged oxygen of nitrile oxide attacks the 
partial positive carbon, within the alkene. In this transition state, it is easier for the 
enaminone to approach towards nitriles oxides as the forces are attractive (Scheme 15). In 
contrast, the nucleophilic attack of the negatively charged oxygen of nitrile oxide onto the 
partially negative carbon, within the alkene, is not favored due to the repulsive 
electrostatic force between the dipole of enaminone and nitrile oxide. In this transition 
state, it is harder for the enaminone to approach towards nitrile oxide as the forces are 
repulsive (Scheme 16). Upon beta elimination of the amine group leaving we then obtain 
our regioselective 3,4-substitued isoxazole.       
 
Figure 3. Resonance contributors of enaminone structure, trans-4-dimethylamino-3-
buten-2-one 2a 
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N Me
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N Me
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Scheme 15. 1,3-Dipolar cycloaddition favored reaction 
 
Scheme 16. 1,3-Dipolar cycloaddition unfavored reaction 
 
Table 3. Oxidative cycloaddition of benzaldehyde oxime 1a with enaminones 2a-j using 
Koser’s reagent 3aa,b  
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aReaction conditions: (E)-Benzaldehyde oxime 1a (0.250 mmol; 1 equiv) and enaminone 
2a-j (0.750 mmol; 3 equiv) with Koser’s reagent 3a (0.500 mmol; 2 equiv) in DCM were 
stirred for 3-24 h at room temperature. bYields of products after column chromatography. 
cNMR yields of products. dReaction conditions: Utilizing (E) enaminone, ethyl-(E)-3-
(pyrrolidine-1-yl)but-2-enoate 2e(E). eReaction conditions: Utilizing (Z) enaminone, ethyl-
(Z)-3-(pyrrolidine-1-yl)but-2-enoate 2e(Z).  
 
4.6. Substrate scope and reaction mechanism study using various enaminones 
At the next step, we attempted to prepare the isoxazole product 4 by the reaction 
of (E)-benzaldehyde oxime 1a with varied enaminone substrates 2a-j using hypervalent 
iodine(III) under similar conditions (Table 3). The reaction of 3-(dimethylamino)acrolein 
2b gave the corresponding product 4ab in 46% yield. The reaction of (E)-4-
(dimethylamino)pent-3-en-2-one 2c gave the corresponding product 4ac in 48% yield. 
The lowered yield of product 4ac can be attributed to the steric hindrance of the methyl 
group on the point of attack on the enaminone substrate, when comparing the reaction to 
the similar unhindered product 4a at 92% yield, but it does not affect the b-elimination 
step of the reaction mechanism (Scheme 17).  
 
Scheme 17. Blank studies with sterically hindered enaminone 
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The reaction corresponding to product 4ae was performed with both (E)- and (Z)-
b-methyl substituted enaminones with cyclic amino groups to determine if the 
stereochemistry of the enaminone substrate affected the reaction and to see the scope of 
the amine leaving group. The reaction of ethyl-(E)-3-(pyrrolidine-1-yl)but-2-enoate 2e(E) 
gave the corresponding product 4ae in 59% and the reaction of ethyl-(Z)-3-(pyrrolidine-
1-yl)but-2-enoate 2e(Z) gave the corresponding product 4ae in 36%. Desired product was 
obtained from both stereoisomer reagents in similar yields. Due to resonance, these 
molecules could be rotating during the reaction meaning the stereochemistry does not 
play an important factor (Figure 4). From this result, we can conclude that the 
stereochemistry of the enaminone substrate does not play an important role in the attack 
of nitrile oxide or the b-elimination step of the 1,3-cycloaddition mechanism (Scheme 
18). We can also conclude that this reaction can proceed with various amine leaving 
groups. The lowered yield corresponding to product 4ae can be attributed to the steric 
hindrance of the methyl on the enaminone substrate, as also seen with product 4ac. The 
lowered yield of product 4ae can also be compared to the reaction of the similar 
unhindered product 4ad at 72% yield when comparing A-values of these functional 
groups.23  
      
Scheme 18. Blank studies with sterically hindered stereoisomers 
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Figure 4. Resonance of stereoisomer enaminones 
 
We also attempted to prepare the isoxazole product 4 with isoxazole fused 
bicyclic heterocycles by the reaction of aldoximes with cyclic enaminones using 
hypervalent iodine(III) reagent under similar conditions. The reaction of 3-
(dimethylamino)-5,5-dimethyl-2-cyclohexen-1-one 1ah gave the corresponding product 
4ah in 22% yield. This lowered yield can be due to the steric hindrance of the cyclic 
enaminone reacting with nitrile oxide.  
The reaction of (1E, 4E)-1-(dimethylamino)-5-phenylpenta-1,4-dien-3-one 1aj 
corresponding to the desired product 4aj was not obtained cleanly as the dimerized form 
of the compound was detected within the compound, from GC-MS confirmation.       
 
4.7. Experimental Section  
4.7.1. General Experimental Remarks  
All reactions were performed under dry argon atmosphere with flame-dried glassware. 
Dichloromethane was distilled immediately prior to use. All commercial reagents were 
ACS reagent grade and used without further purification. Melting points were determined 
in an open capillary tube with a Mel-temp II melting point apparatus. Infrared spectra 
were recorded as a NaCl pellet on a PerkinElmer 1600 series FT-IR spectrophotometer. 
1H NMR spectra were recorded on a Varian Inova 500 and 300 MHz NMR spectrometer. 
13C NMR spectra were recorded on a Varian Inova 500 and 300 MHz NMR 
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spectrometer, at 125 and 75 MHz. Chemical shifts are reported in parts per million 
(ppm). 1H and 13C chemical shifts are referenced relative to the tetramethylsilane. The 
known hypervalent iodine(III) compound, Koser’s reagent, was prepared according to the 
reported procedures.24  
 
4.7.2. General procedure for generation of aldoxime 
Benzaldehyde (5 mmol), NH2OH•HCl (10 mmol), and pyridine (20mmol) were added in 
dichloromethane (25 mL). The reaction was stirred at room temperature for 20 hours. 
After completion of the reaction, water and HCl were added and the reaction was 
extracted in dichloromethane. The organic phase was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification of column chromatography (hexane-
ethyl acetate = 9:1 to 1:1) afforded analytically pure products.       
 
4.7.3. General procedure for oxidative cycloaddition of aldoximes using Koser’s 
reagent  
Aldoxime 1 (0.250 mmol) and trans-4-dimethylamino-3-buten-2-one 2a (85 mg, 0.750 
mmol) were added to a solution of Koser’s reagent 3a (196 mg, 0.500 mmol) in dry 
dichloromethane (2 mL). The reaction was stirred at room temperature for 1.5-24 h. After 
completion of the reaction, 5% aqueous Na2S2O3 (5 mL) was added, and the mixture was 
extracted with dichloromethane. The organic phase was dried over anhydrous Na2SO4 
and concentrated under reduced pressure. Purification by column chromatography 
(hexane−ethyl acetate = 9:1 to 1:1) afforded analytically pure products.  
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1-(3-Phenylisoxazol-4-yl)ethan-1-one, 4a 
 
Reaction of (E)-benzaldehyde oxime 1a (30 mg, 0.250 mmol) according to the general  
procedure afforded 43 mg (92%) of product 4a, isolated as a white solid: mp 78.0-
78.8 °C, (lit mp25: 83.0°C); IR (neat) cm−1 3366, 3127, 3091, 3006, 2923, 2852, 1685, 
1560, 1445, 1387; 1H NMR (300 MHz, CDCl3): δ 9.00 (s, 1H), 7.72-7.65 (m, 2H), 7.54-
7.42 (m, 3H), 2.44 (s, 3H); 13C NMR (300 MHz, CDCl3): δ 190.4, 163.4, 160.8, 130.3, 
129.4, 128.4, 127.4, 120.9, 29.7; HRMS (APCI-positive ionization): calcd for C11H10NO2 
([M+H]+): 188.0712, found: 188.0727.  
S1: 1-(3-Phenylisoxazol-4-yl)ethan-1-one, 4a 
 
X-ray crystallography was obtained by slow evaporation of dichloromethane.  
 
Large scale: Reaction of (E)-benzaldehyde oxime 1a (121 mg, 1 mmol) and trans-4-
dimethylamino-3-buten-2-one (339 mg, 3 mmol) were added to a solution of Koser’s 
reagent (784 mg, 2 mmol) in dichloromethane (9 mL) affording 159 mg (85%) of product 
4a, isolated as a white solid: mp 78.0-78.8 °C (lit mp25: 83.0°C); IR (neat) cm−1 3366, 
3127, 3091, 3006, 2923, 2852, 1685, 1560, 1445, 1387; 1H NMR (300 MHz, CDCl3): δ 
9.00 (s, 1H), 7.72-7.65 (m, 2H), 7.54-7.42 (m, 3H), 2.44 (s, 3H); 13C NMR (75 MHz, 
ON
O Me
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CDCl3): δ 190.4, 163.4, 160.8, 130.3, 129.4, 128.4, 127.4, 120.9, 29.7; HRMS (APCI-
positive ionization): calcd for C11H10NO2 ([M+H]+): 188.0712, found: 188.0727.  
 
1-(3-(4-Chlorophenyl)isoxazol-4-yl)ethan-1-one26, 4b 
 
Reaction of (E)-4-chlorobenzaldehyde oxime 1b (39 mg, 0.250 mmol) according to the 
general procedure afforded 47 mg (85%) of product 4b, isolated as a white solid: mp 
111.7-112.1 °C; IR (neatl) cm−1 3345, 3113, 3077, 2923, 2856, 1691, 1577, 1413, 1383, 
1095; 1H NMR (300 MHz, CDCl3): δ 9.01 (s, 1H), 7.68 (d. J=8.4 Hz, 2H), 7.44 (d, J=8.4 
Hz, 2H), 2.49 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 190.0, 163.6, 159.9, 136.5, 130.8, 
128.6, 125.8, 120.5, 29.7; HRMS (APCI-positive ionization): calcd for C11H935ClNO2 
([M+H]+): 222.0322, found: 222.0332.  
 
1-(3-(2-Chlorophenyl)isoxazol-4-yl)ethan-1-one, 4c 
 
Reaction of (E)-2-chlorobenzaldehyde oxime 1c (39 mg, 0.250 mmol) according to the 
general procedure afforded 45 mg (81%) of product 4c, isolated as a white solid: mp 
62.1-62.6 °C; IR (neat) cm−1 3365, 3139, 3095, 2924, 2854, 1685, 1563, 1437, 1387, 
1118; 1H NMR (300 MHz, CDCl3): δ 9.01 (s, 1H), 7.55-7.34 (m, 4H), 2.34 (s, 3H); 13C 
NMR (75 MHz, CDCl3): δ 189.9, 162.1, 158.9, 133.8, 131.2, 131.0, 129.7, 127.4, 126.8, 
ON
O Me
Cl
ON
O Me
Cl
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122.1, 28.9; HRMS (APCI-positive ionization): calcd for C11H935ClNO2 ([M+H]+): 
222.0322, found: 222.0331.  
 
1-(3-(3-Chlorophenyl)isoxazol-4-yl)ethan-1-one, 4d 
 
Reaction of (E)-3-chlorobenzaldehyde oxime 1d (39 mg, 0.250 mmol) according to the 
general procedure afforded 54 mg (97%) of product 4d, isolated as a white solid: mp 
118.3-119.6 °C; IR (neat) cm−1 3351, 3123, 3092, 2924, 2853, 1689, 1557, 1409, 1390, 
1121; 1H NMR (300 MHz, CDCl3): δ 9.02 (s, 1H), 7.72 (d. J=1.5 Hz, 1H), 7.60 (dd, 
J=7.5 Hz, 1.5 Hz, 1H), 7.49-7.45 (m, 1H), 7.42-7.37 (m, 1H), 2.48 (s, 3H); 13C NMR (75 
MHz, CDCl3): δ 190.0, 163.7, 159.7, 134.2, 130.3, 129.6, 129.5, 129.1, 127.7, 120.6, 
29.7; HRMS (APCI-positive ionization): calcd for C11H935ClNO2 ([M+H]+): 222.0322, 
found: 222.0333.  
 
1-(3-(2,6-Dichlorophenyl)isoxazol-4-yl)ethan-1-one, 4e 
 
Reaction of (E)-2,6-dichlorobenzaldoxime 1e (48 mg, 0.250 mmol) according to the 
general procedure afforded 58 mg (91%) of product 4e, isolated as a white solid: mp 
107.4-108.8°C, (lit mp27: 118-120°C); IR (neat) cm−1 3350, 3134, 3091, 3066, 2925, 
2857, 1688, 1567, 1424, 1391, 1095; 1H NMR (500 MHz, CDCl3): δ 9.09 (s, 1H), 7.44 
ON
O Me
Cl
ON
O MeCl
Cl
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(d. J=7.5 Hz, 1H), 7.41-7.36 (m, 2H), 2.35 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
189.4, 162.7, 156.8, 135.3, 131.5, 128.0, 127.1, 121.8, 28.8; HRMS (APCI-positive 
ionization): calcd for C11H835Cl2NO2 ([M+H]+): 255.9932, found: 255.9945.  
 
4-(4-Acetylisoxazol-3-yl)phenyl acetate, 4f 
 
Reaction of (E)-4-((hydroxyimino)methyl)phenyl acetate 1f (45 mg, 0.250 mmol) 
according to the general procedure afforded 50 mg (81%) of product 4f, isolated as a 
white solid: mp 83.5-84.3 °C; IR (neat) cm−1 3366, 3131, 3091, 2926, 2854, 1748, 1685, 
1560, 1419, 1365, 1165, 1111; 1H NMR (500 MHz, CDCl3): δ 9.00 (s, 1H), 7.77 (d, 
J=8.8 Hz, 2H), 7.20 (d, J=8.8 Hz, 2H), 2.47 (s, 3H), 2.32 (s, 3H); 13C NMR (300 MHz, 
CDCl3): δ 190.2, 169.1, 163.7, 160.0, 152.2, 130.8, 124.9, 121.6, 120.6, 29.7, 21.2; 
HRMS (APCI-positive ionization): calcd for C13H12NO4 ([M+H]+): 246.0766, found: 
246.0774.  
 
1-(3-(4-Nitrophenyl)isoxazol-4-yl)ethan-1-one27, 4g 
 
Reaction of (E)-4-nitrobenzaldehyde 1g (42 mg, 0.250 mmol) according to the general 
procedure afforded 44 mg (76%) of product 4g, isolated as a white solid: mp 182.5-
183.3 °C; IR (neat) cm−1 3365, 3137, 3083, 3066, 2845, 1691, 1562, 1510, 1420, 1350, 
ON
O Me
AcO
ON
O Me
O2N
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856; 1H NMR (300 MHz, CDCl3): δ 9.08 (s, 1H), 8.33 (d, J=9.5 Hz, 2H), 7.94 (d, J=9.5 
Hz, 2H), 2.56 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 189.8, 163.9, 159.2, 148.9, 133.7, 
130.7, 123.4, 120.5, 29.7; HRMS (APCI-positive ionization): calcd for C11H9N2O4 
([M+H]+): 233.0562, found: 233.0567. 
 
1-(3-(3-Nitrophenyl)isoxazol-4-yl)ethan-1-one, 4h 
 
Reaction of (E)-3-nitrobenzaldehyde oxime 1h (42 mg, 0.250 mmol) according to the 
general procedure afforded 57 mg (98%) of product 4h, isolated as a light yellow solid: 
mp 118.7-119.3 °C; IR (neat) cm−1 3359, 3094, 2927, 2854, 1685, 1560, 1539, 1428, 
1390, 1349, 861; 1H NMR (300 MHz, CDCl3): δ 9.11 (s, 1H), 8.65 (t, J=1.5 Hz, 1H), 
8.35 (dd, J=8.4 Hz, 1.5 Hz, 1H), 8.09 (d, J=7.5 Hz, 1H), 7.70-7.61 (m, 1H), 2.56 (s, 3H); 
13C NMR (75 MHz, CDCl3): δ 189.7, 163.9, 159.0, 147.9, 135.3, 129.2, 129.0, 124.8, 
124.6, 120.2, 29.5; HRMS (APCI-positive ionization): calcd for C11H9N2O4 ([M+H]+): 
233.0562, found: 233.0576.  
 
Methyl 4-(4-acetylisoxazol-3-yl)benzoate, 4i 
 
Reaction of methyl(E)-4-((hydroxyimino)methyl) benzoate 1i (45 mg, 0.250 mmol) 
according to the general procedure afforded 50 mg (82%) of product 4i, isolated as a 
ON
O Me
O2N
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O Me
MeO2C
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white solid: mp 116.2-117.4 °C; IR (neat) cm−1 3371, 3093, 3005, 2916, 2849, 1705, 
1689, 1559, 1413, 1119; 1H NMR (500 MHz, CDCl3): δ 9.06 (s, 1H), 8.13 (d, J=8.3 Hz, 
2H), 7.79 (d, J=8.3 Hz, 2H), 3.94 (s, 3H), 2.49 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
190.0, 166.5, 163.8, 160.1, 131.8, 131.6, 129.5, 129.5, 120.7, 52.3, 29.7; HRMS (APCI-
positive ionization): calcd for C13H12NO4 ([M+H]+): 246.0766, found: 246.0779.  
 
4-(4-Acetylisoxazol-3-yl)benzonitrile, 4j 
 
Reaction of (E)-4-((hydroxyamino)methyl) benzonitrile 1j (37 mg, 0.250 mmol) 
according to the general procedure afforded 50 mg (94%) of product 4j, isolated as a 
white solid: mp 181.3-181.7 °C; IR (neat) cm−1 3370, 3134, 3090, 3057, 2922, 2232, 
1689, 1577, 1421, 1386; 1H NMR (300 MHz, CDCl3): δ 9.08 (s, 1H), 7.87 (d, J=7.1 Hz, 
2H), 7.75 (d, J=7.1 Hz, 2H), 2.54 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 189.8, 163.9, 
159.4, 131.9, 130.2, 120.4, 118.3, 113.9, 29.6; HRMS (APCI-positive ionization): calcd 
for C12H9N2O2 ([M+H]+): 213.0664, found: 213.0667. 
 
1-(3-(4-Bromophenyl)isoxazol-4-yl)ethan-1-one, 4k 
 
Reaction of (E)-4-bromobenzaldehyde oxime 1k (50 mg, 0.250 mmol) according to the 
general procedure afforded 60 mg (90%) of product 4k, isolated as a white solid: mp 
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111.5-112.1 °C; IR (neat) cm−1 3348, 3111, 3082, 3068, 2925, 2854, 1692, 1575, 1408, 
1380; 1H NMR (300 MHz, CDCl3): δ 9.02 (s, 1H), 7.64-7.58 (m, 4H), 2.49 (s, 3H); 13C 
NMR (75 MHz, CDCl3): δ 190.3, 163.9, 160.2, 131.8, 131.2, 126.5, 125.1, 120.7, 29.9; 
HRMS (APCI-positive ionization): calcd for C11H979BrNO2 ([M+H]+): 265.9817, found: 
265.9828.  
 
1-(3-(Benzo[d][1,3]dioxol-5-yl)isoxazol-4-yl)ethan-1-one, 4l 
 
Reaction of Piperonaldoxime 1l (41 mg, 0.250 mmol) according to the general procedure 
afforded 48 mg (83%) of product 4l, isolated as a white solid: mp 133.2-133.6 °C; IR 
(neat) cm−1 3339, 3091, 3025, 2908, 1673, 1562, 1466, 1397, 1260, 1242, 1150; 1H NMR 
(500 MHz, CDCl3): δ 8.97 (s, 1H), 7.25 (dd, J=7.8 Hz, 1.8 Hz, 1H), 7.19 (d, J=1.8 Hz, 
1H), 6.89 (d, J=7.8 Hz, 1H), 6.03 (s, 2H), 2.47 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
190.4, 163.6, 160.3, 149.4, 147.6, 123.9, 120.8, 120.6, 109.8, 108.3, 101.5, 29.8; HRMS 
(APCI-positive ionization): calcd for C12H10NO4 ([M+H]+): 232.0610, found: 232.0626.  
 
1-(3-(5-Nitrofuran-2-yl)isoxazol-4-yl)ethan-1-one, 4m 
   
Reaction of (E)-5-nitrofuran-2-carbaldehyde oxime 1m (39 mg, 0.250 mmol) according 
to the general procedure afforded 52 mg (93%) of product 4m, isolated as a yellow solid: 
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mp 133.7-135.9 °C; IR (neat) cm−1 3363, 3165, 3120, 2926, 2854, 1687, 1557, 1542, 
1406, 1359, 1346; 1H NMR (500 MHz, CDCl3): δ 9.11 (s, 1H), 7.81 (d, J=3.9 Hz, 1H), 
7.42 (d, J=3.9 Hz, 1H), 2.61 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 189.3, 164.2, 150.1, 
143.9, 120.5, 118.2, 112.1, 29.6 (1 peak overlap); HRMS (APCI-positive ionization): 
calcd for C9H7N2O5 ([M+H]+): 223.0355, found: 223.0366. 
 
1-(3-(p-Tolyl)isoxazol-4-yl)ethan-1-one, 4n 
 
Reaction of (E)-4-methylbenzaldehyde oxime 1n (34 mg, 0.250 mmol) according to the 
general procedure afforded 37 mg (74%) of product 4n, isolated as a white solid: mp 
86.3-88.0 °C; IR (neat) cm−1 3372, 3057, 2918, 2849, 1690, 1556, 1417, 1381; 1H NMR 
(300 MHz, CDCl3): δ 8.97 (s, 1H), 7.58 (d, J=7.5 Hz, 2H), 7.27 (d, J=7.5 Hz, 2H), 2.43 
(s, 3H), 2.41 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 190.4, 163.3, 160.7, 140.4, 129.2, 
129.0, 124.3, 120.8, 29.7, 21.4; HRMS (APCI-positive ionization): calcd for C12H12NO2 
([M+H]+): 202.0868, found: 202.0876.   
 
1-(3-(2,4-Dimethylphenyl)isoxazol-4-yl)ethan-1-one, 4o 
 
Reaction of (E)-2,4-dimethylbenzaldehyde oxime 1o (37 mg, 0.250 mmol) according to 
the general procedure afforded 51 mg (95%) of product 4o, isolated as a white solid: mp 
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86.0-86.9 °C; IR (neat) cm−1 3363, 3094, 3008, 2924, 2859, 1696, 1563, 1385, 1361; 1H 
NMR (500 MHz, CDCl3): δ 9.01 (s, 1H), 7.17 (d, J=7.8 Hz, 1H), 7.13 (s, 1H), 7.09 (d, 
J=7.8 Hz, 1H), 2.37 (s, 3H), 2.23 (s, 3H), 2.16 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
190.6, 162.7, 160.6, 139.9, 136.9, 133.2, 129.6, 126.5, 124.3, 122.2, 29.2, 21.3, 19.7; 
HRMS (APCI-positive ionization): calcd for C13H14NO2 ([M+H]+): 216.1025, found: 
216.1036.   
 
1-(3-(2,6-Dimethylphenyl)isoxazol-4-yl)ethan-1-one, 4p 
 
Reaction of 2,6-dimethylbenzaldehyde oxime 1p (37 mg, 0.250 mmol) according to the 
general procedure afforded 32 mg (59%) of product 4p, isolated as a white solid: mp 
96.7-97.9 °C; IR (neat) cm−1 3359, 3093, 2955, 2925, 2858, 1685, 1565, 1466, 1386; 1H 
NMR (500 MHz, CDCl3): δ 9.09 (s, 1H), 7.28 (d, J=7.8 Hz, 1H), 7.14 (d, J=7.8 Hz, 2H), 
2.13 (s, 3H), 2.09 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 190.6, 163.1, 159.7, 137.1, 
129.6, 127.6, 127.2, 122.1, 28.7, 20.2; HRMS (APCI-positive ionization): calcd for 
C13H14NO2 ([M+H]+): 216.1025, found: 216.1032.  
 
1-(3-(4-Methoxyphenyl)isoxazol-4-yl)ethan-1-one, 4q 
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Reaction of (E)-4-methoxybenzaldehyde oxime 1q (38 mg, 0.250 mmol) according to the 
general procedure afforded 39 mg (72%) of product 4q, isolated as a white solid: mp 
95.4-96.7 °C; IR (neat) cm−1 3371, 3056, 2965, 2917, 2849, 1693, 1613, 1425, 1383, 
1255, 1036; 1H NMR (300 MHz, CDCl3): δ 8.97 (s, 1H), 7.68 (d, J=9.0 Hz, 2H), 6.98 (d, 
J=9.0 Hz, 2H), 3.86 (s, 3H), 2.46 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 190.4, 163.4, 
161.1, 160.3, 130.8, 120.6, 119.4, 113.7, 55.3, 29.7; HRMS (APCI-positive ionization): 
calcd for C12H12NO3 ([M+H]+): 218.0817, found: 218.0825.  
 
1-(3-(Naphthalen-2-yl)isoxazol-4-yl)ethan-1-one, 4r 
 
Reaction of (E)-2-napthaldehyde oxime 1r (43 mg, 0.250 mmol) according to the general 
procedure afforded 52 mg (88%) of product 4r, isolated as a white solid: mp 93.5-
95.1 °C; IR (neat) cm−1 3373, 3091, 3056, 2925, 2854, 1691, 1561, 1434, 1394, 862, 831, 
822; 1H NMR (500 MHz, CDCl3): δ 9.00 (s, 1H), 8.26 (s, 1H), 7.94-7.89 (m, 2H), 7.87 
(d, J=8.0 Hz, 1H), 7.74 (d, 8.0 Hz, 1H), 7.57-7.48 (m, 2H), 2.43 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 190.3, 163.6, 160.7, 133.9, 132.8, 129.5, 128.6, 127.9, 127.7, 127.2, 
126.5, 126.2, 124.7, 120.9, 29.7; HRMS (APCI-positive ionization): calcd for C15H12NO2 
([M+H]+): 238.0868, found: 238.0879.  
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1-(3-(Naphthalen-1-yl)isoxazol-4-yl)ethan-1-one, 4s 
 
Reaction of (E)-1-napthaldehyde oxime 1s (43 mg, 0.250 mmol) according to the general  
procedure afforded 52 mg (88%) of product 4s, isolated as a white solid: mp 139.8-
141.1 °C; IR (neat) cm−1 3364, 3090, 3060, 2923, 2854, 1685, 1564, 1423, 1383, 803; 1H 
NMR (500 MHz, CDCl3): δ 9.11 (s, 1H), 8.13-7.97 (m, 1H), 7.92 (d, J=8.0 Hz, 1H), 
7.62-7.54 (m, 3H), 7.52 (t, J=7.3 Hz, 1H), 7.49-7.44 (m, 1H), 2.06 (s, 3H); 13C NMR 
(125 MHz, CDCl3): δ 190.5, 162.0, 159.7, 133.4, 131.8, 130.5, 128.5, 128.1, 127.1, 
126.4, 125.2. 125.0, 124.7, 123.0, 29.1; HRMS (APCI-positive ionization): calcd for 
C15H12NO2 ([M+H]+): 238.0868, found: 238.0869.  
 
1-(3-(4-(Methylthio)phenyl)isoxazol-4-yl)ethan-1-one, 4t 
 
Reaction of (E)-4-(methylthio)benzaldehyde 1t (42 mg, 0.250 mmol) according to the 
general procedure afforded 20 mg (34%) of product 4t, isolated as a white solid: mp 
93.1-94.8 °C; IR (neat) cm−1 3363, 3099, 2924, 2854, 1685, 1573, 1411, 1379, 736; 1H 
NMR (500 MHz, CDCl3): δ 8.99 (s, 1H), 7.65 (d, J=8.5 Hz, 2H), 7.31 (d, J=8.5 Hz, 2H), 
2.52 (s, 3H), 2.47 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 190.3, 163.5, 160.3, 141.8, 
129.7, 125.6, 123.6, 120.7, 29.8, 15.2; HRMS (APCI-positive ionization): calcd for 
C12H12NO2S ([M+H]+): 234.0589, found: 234.0592. 
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S2: 1-(3-(4-(methylthio)phenyl)isoxazol-4-yl)ethan-1-one, 4t 
 
X-ray crystallography was obtained by slow evaporation of dichloromethane.  
 
1-(3-([1,1'-Biphenyl]-4-yl)isoxazol-4-yl)ethan-1-one, 4u 
 
Reaction of (E)-([1,1'-biphenyl]-4-carbaldehyde oxime 1u (49 mg, 0.250 mmol) 
according to the general procedure afforded 49 mg (74%) of product 4u, isolated as a 
white solid: mp 146.8-147.7 °C; IR (neat) cm−1 3353, 3126, 3083, 2926, 2856, 1692, 
1572, 1446, 1411; 1H NMR (300 MHz, CDCl3): δ 9.00 (s, 1H), 7.79 (d, J=7.8 Hz, 2H), 
7.68 (d, J=7.8 Hz, 2H), 7.63 (d, J=8.1 Hz, 2H), 7.50-7.42 (m, 1H), 7.37 (t, J=6.9 Hz, 1H), 
2.47 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 190.5, 163.7, 160.6, 143.2, 140.4, 130.0, 
129.0, 127.9 127.3, 127.2, 126.3, 120.9, 29.9; HRMS (APCI-positive ionization): calcd 
for C17H14NO2 ([M+H]+): 264.1025, found: 264.1032.  
S3: 1-(3-([1,1'-biphenyl]-4-yl)isoxazol-4-yl)ethan-1-one, 4u 
 
X-ray crystallography was obtained by slow evaporation of dichloromethane.  
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(E)-1-(3-Styrylisoxazol-4-yl)ethan-1-one, 4v 
 
Reaction of (1E, 2E)-cinnamaldehyde oxime 1v (37 mg, 0.250 mmol) according to the 
general procedure afforded 33 mg (62%) of product 4v, isolated as a white solid: mp 
94.9-96.3 °C; IR (neat) cm−1 3345, 3068, 3026, 2925, 2854, 1682, 1565, 1408, 1362, 854; 
1H NMR (500 MHz, CDCl3): δ 8.91 (s, 1H), 7.68 (d, J=16.8 Hz, 1H), 7.58 (d, J=7.5 Hz, 
1H), 7.47 (d, J=16.8 Hz, 1H), 7.41-7.36 (m, 2H), 7.33 (t, J=7.3 Hz, 1H), 2.52 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 190.9, 162.9, 158.2, 137.3, 135.9, 129.1, 128.8, 127.4, 120.0, 
113.6, 29.4; HRMS (APCI-positive ionization): calcd for C13H12NO2 ([M+H]+): 
214.0808, found: 214.0879. 
 
1-(3-Phenethylisoxazol-4-yl)ethan-1-one, 4w 
 
Reaction of (E)-3-phenylpropanal oxime 1w (37 mg, 0.250 mmol) according to the 
general procedure afforded 30 mg (56%) of product 4w, isolated as a white solid: mp 
52.8-53.9 °C; IR (neat) cm−1 3353, 3104, 3064, 3028, 2934, 2865, 1685, 1578, 1412, 
1363; 1H NMR (500 MHz, CDCl3): δ 8.85 (s, 1H), 7.33-7.25 (m, 4H), 7.23-7.18 (m, 1H), 
3.24 (dd, J=10.5 Hz, 8.3 Hz, 2H), 3.01 (dd, J=10.5 Hz, 8.3 Hz, 2H), 2.48 (s, 3H); 13C 
NMR (125 MHz, CDCl3): δ 190.8, 162.6, 161.4, 140.8, 128.5, 128.4, 126.2, 120.4, 33.6, 
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29.1, 27.6; HRMS (APCI-positive ionization): calcd for C13H14NO2 ([M+H]+): 216.1025, 
found: 216.1032.  
 
1-(3-Propylisoxazol-4-yl)ethan-1-one, 4x 
 
Reaction of butyraldoxime 1x (24 mg, 0.250 mmol) according to the general procedure 
afforded 18 mg (46%) of product 4x, isolated as a clear oil; IR (neat) cm−1 3356, 3101, 
2966, 2936, 2876, 1680, 1577, 1413, 1363; 1H NMR (500 MHz, CDCl3): δ 8.87 (s, 1H), 
2.91 (t, J=7.5 Hz, 2H), 2.48 (s, 3H), 1.72 (sext, J=7.5 Hz, 2H), 0.99 (t, J=7.5 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 190.3, 162.0, 161.5, 119.9, 29.9, 28.8, 20.3, 13.3; HRMS 
(APCI-positive ionization): calcd for C8H12NO2 ([M+H]+): 154.0868, found: 154.0880. 
 
4.8.4. General procedure for oxidative cycloaddition of (E)-benzaldehyde oxime and 
enaminones using Koser’s reagent.  
(E)-benzaldehyde oxime 1a (30 mg, 0.250 mmol) and enaminone 2 (0.750 mmol) were 
added to a solution of Koser’s reagent 3a (196 mg, 0.500 mmol) in dry dichloromethane 
(2 mL). The reaction was stirred at room temperature for 3-24 h. After completion of the 
reaction, 5% aqueous Na2S2O3 (5 mL) was added, and the mixture was extracted with 
dichloromethane. The organic phase was dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. Purification by column chromatography (hexane−ethyl acetate = 
9:1 to 1:1) afforded analytically pure products.  
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3-Phenylisoxazole-4-carbaldehyde, 4ab 
 
Reaction of 3-(dimethylamino)acrolein 2b (74 mg, 0.750 mmol) according to the general 
procedure afforded 20 mg (46%) of product 4ab, isolated as a white solid: mp 45.5-
46.9 °C (lit mp: 41-42oC)28 ; IR (neat) cm−1 3375, 3125, 3093, 2926, 2854, 2751, 1696, 
1559, 1448, 1384; 1H NMR (500 MHz, CDCl3): δ 10.0 (s, 1H), 9.09 (s, 1H), 7.80 (dd, 
J=7.5 Hz, 2.0 Hz, 2H), 7.57-7.50 (m, 3H); 13C NMR (125 MHz, CDCl3): δ 182.7, 165.2, 
160.5, 130.8, 129.1, 129.0, 126.7, 121.0; HRMS (APCI-positive ionization): calcd for 
C10H8NO2 ([M+H]+): 174.0555, found: 174.0573.  
 
1-(5-Methyl-3-phenylisoxazol-4-yl)ethan-1-one, 4ac 
 
Reaction of (E)-4-(dimethylamino)pent-3-en-2-one 2c (95 mg, 0.750 mmol) according to 
the general procedure afforded 24 mg (48%) of product 4ac, isolated as a white solid: mp 
57.9-58.7 °C (lit mp29: 61.3-61.7 °C); IR (neat) cm−1 3345, 3004, 3065, 2927, 2854, 
1683, 1570, 1409, 1360; 1H NMR (500 MHz, CDCl3): δ 7.53-7.47 (m, 5H), 2.71 (s, 3H), 
2.09 (s, 3H); 13C NMR (500 MHz, CDCl3): δ 193.3, 174.7, 161.9, 130.0, 129.1, 129.0, 
128.7, 117.3, 30.6, 13.6; HRMS (APCI-positive ionization): calcd for C12H12NO2 
([M+H]+): 202.0868, found: 202.0879.  
 
ON
Ph
O H
ON
Ph
O Me
Me
 39 
Ethyl-3-phenylisoxazole-4-carboxylate30, 4ad 
  
Reaction of ethyl-N,N-dimethylamino-acrylate 2d (107 mg, 0.750 mmol) according to 
the general procedure afforded 42 mg (72%) of product 4ad, isolated as a yellow oil; IR 
(neat) cm−1 3450, 3066, 3101, 2984, 2940, 1719, 1565, 1448, 1387; 1H NMR (500 MHz, 
CDCl3): δ 9.01 (s, 1H), 7.77 (dd, J=8.0 Hz, 2.0 Hz, 2H), 7.52-7.43 (m, 3H), 4.29 (q, J=7.0 
Hz, 2H), 1.30 (t, J=7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 164.1, 161.3, 160.9, 
130.2, 129.5, 128.2, 127.3, 113.0, 61.1, 14,1; HRMS (APCI-positive ionization): calcd 
for C12H12NO3 ([M+H]+): 218.0817, found: 218.0827.  
 
Ethyl 5-methyl-3-phenylisoxazole-4-carboxylate, 4ae 
  
Reaction of ethyl-(E)-3-(1-pyrrolindinyl)crotonate 2e(E) (137 mg, 0.750 mmol) and 
ethyl-(Z)-3-(1-pyrrolindinyl)crotonate 2e(Z) (137.4 mg, 0.750 mmol) according to the 
general procedure afforded 34 mg (59%) and 21 mg (36%)of product 4ae respectively, 
isolated as a white solid: mp 46.6-47.6 °C (lit mp31: 49 °C); IR (neat) cm−1 3413, 3064, 
2984, 2934, 2873, 1715, 1604, 1448, 1425, 1150; 1H NMR (500 MHz, CDCl3): δ 7.64-
7.59 (m, 2H), 7.48-7.39 (m, 3H), 4.23 (q, J=7.0 Hz, 2H), 2.73 (s, 3H), 1.22 (t, J=7.0 Hz, 
3H); 13C NMR (500 MHz, CDCl3): δ 175.8, 162.6, 162.0, 129.7, 129.4, 128.5, 127.9, 
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108.5, 60.7, 14.0, 13.6; HRMS (APCI-positive ionization): calcd for C13H14NO3 
([M+H]+): 232.0974, found: 232.0990.  
 
2-Methyl-1-(3-phenylisoxazol-4-yl)propan-1-one, 4af 
  
Reaction of (E)-1-(dimethylamino)-4-methylpent-1-en-3-one 2f (106 mg, 0.750 mmol) 
according to the general procedure afforded 45 mg (84%) of product 4af, isolated as a 
light yellow oil; IR (neat) cm−1 3361, 3090, 2974, 2934, 2875, 1688, 1558, 1444, 1387; 
1H NMR (500 MHz, CDCl3): δ 8.98 (s, 1H), 7.67 (dd, J=8.3 Hz, 1.8 Hz, 2H), 7.51-7.43 
(m, 3H), 3.06 (sept, J=7.0 Hz, 1H), 1.18 (d, J=7.0 Hz, 6H); 13C NMR (500 MHz, CDCl3): 
δ 197.7, 162.4, 161.3, 130.2, 129.3, 128.3, 127.5, 119.3, 39.9, 18.8; HRMS (APCI-
positive ionization): calcd for C13H14NO2 ([M+H]+): 216.1025, found: 216.1032.  
 
Cyclopropyl(3-phenylisoxazol-4-yl)methanone, 4ag 
  
Reaction of 1-cyclopropyl-3-(dimethylamino)-2-propen-1-one 2g (104 mg, 0.750 mmol) 
according to the general procedure afforded 52.7 mg (99%) of product 4ag, isolated as a 
yellow oil; IR (neat) cm−1 3337, 3090, 3011, 2926, 2854, 1685, 1557, 1448; 1H NMR 
(500 MHz, CDCl3): δ 9.06 (s, 1H), 7.72-7.67 (m, 2H), 7.51-7.43 (m, 3H), 2.18-2.11 (m, 
1H), 1.23 (dt, J-7.5 Hz, 3.5 Hz, 2H), 0.96 (dq, J=8.0 Hz, 3.5 Hz, 2H); 13C NMR (500 
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MHz, CDCl3): δ 193.5, 162.6, 160.7, 130.2, 129.4, 128.3, 127.6, 121.5, 20.8, 12.1; 
HRMS (APCI-positive ionization): calcd for C14H14NO2 ([M+H]+): 214.0868, found: 
214.0881. 
 
6,6-Dimethyl-3-phenyl-6,7-dihydrobenzo[d]isoxazol-4(5H)-one, 4ah 
 
Reaction of 3-(dimethylamino)-5,5-dimethyl-2-cyclohexen-1-one 2h (125 mg, 0.750 
mmol) according to the general procedure afforded 13 mg (22%) of product 4ah, isolated 
as a white solid mp: 88.2-90.6 °C (lit mp32: 101-103oC); 1H NMR (500 MHz, CDCl3): δ 
8.11-8.06 (m, 2H), 7.50-7.43 (m, 3H), 2.92 (s, 2H), 2.47 (s, 2H), 1.19 (s, 6H); 13C NMR 
(500 MHz, CDCl3): δ 191.5, 181.7, 159.8, 130.6, 129.1, 128.4, 127.4, 113.1, 53.2, 37.1, 
28.3; HRMS (APCI-positive ionization): calcd for C15H16NO2 ([M+H]+): 242.1181, 
found: 242.1188. 
 
 
 
 
 
 
 
 
 
ON
Ph
O Me
Me
 42 
4.8. Conclusion and Recommendation 
We developed a strategy to prepare 31 isoxazoles through hypervalent iodine(III) 
cycloaddition of aldoximes with enaminones. In this procedure, Koser’s reagent was used 
as the oxidant to convert aldoximes to their respective nitrile oxide species. Further study 
on the reaction mechanism showed the that formation of reactive nitrile oxide species 
proceeds by ligand exchange and reductive elimination. The active nitrile oxide species 
then reacts with respective enaminone substrates by 1,3-dipolar cycloaddition to create 5-
membered ring isoxazole compounds. Aldoximes with electron-donating and electron-
withdrawing groups reacted with the enaminone substrates to afford the 3,4 isoxazole in 
moderate to good yields with minimal limitation by steric hindrance. Furthermore, 
aldoximes containing functional group that were susceptible to oxidation competitive had 
lower yields of desired product as side reactions competed with the 1,3-dipolar 
cycloaddition reaction. The identity and characterization of all compounds were validated 
by 1H NMR and 13C NMR. FT-IR and ESI-MS were also recorded for all compounds. 
Structures of 3 isoxazole derivatives were established by X-ray crystallography. For 
future research, the generation of new isoxazole derivatives will be further studied 
utilizing hypervalent iodine(III).  
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5.2. Appendices  
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